Curcumin effect on non-amyloidogenic pathway for preventing Alzheimer’s disease

Abstract

Amyloid beta (Aβ) plaque deposition is a pathological feature of Alzheimer’s disease (AD) that is characterized by dementia. Therapies approaches affecting Aβ synthesis and accumulation are necessary for improving AD. The present review, as the future prospective study, focuses on the possible effect of curcumin on the non-amyloidogenic pathways for inhibiting the Aβ plaque in AD. Activators of non-amyloidogenic pathways emerge as a novel strategy in attenuating Aβ. Drugs and natural compounds can affect neurotrophic signaling pathways including protein kinase C (PKC), tyrosine kinase (TK), mitogen-activated protein kinase (MAPK)-extracellular signal-regulated kinase (ERK) signaling, and Ca2+ signaling as wells serotonergic and acetylcholine systems, resulting to stimulate nonamyloidogenic pathways. Curcumin, active constituent of Curcuma longa L. (turmeric), has a potent effect against AD through prevention Aβ generation and deposition. With attention to the effect of curcumin on the molecular mechanism behind the nonamyloidogenic pathways, we suggest designing more studies to identify curcumin as a therapeutic restricting AD agent via its impact on the non-amyloidogenic pathway.

Body Fluid Biomarkers for Alzheimer’s Disease—An Up-To-Date Overview

“…Neurodegeneration is the underlying factor for many debilitating and incurable age-dependent disorders [3,7,8]. The prevalence of neurodegenerative disorders is continuously increasing as a consequence of the dramatic rise in life expectancy due to scientific achievements and progress, thus posing a significant threat to human health [5,7,9,10].…”

Biosensors-on-Chip: An Up-to-Date Review

“…Recent years have witnessed an increasing number of studies regarding the identification of neurodegeneration-related biomarkers [110][111][112]. In this regard, various biomarkers including amyloid-β peptides, tau proteins, neurofilament light, for neuronal injury, neurogranin, BACE1, SNAP-25, and synaptotagmin for synaptic dysfunction and/or loss, sTREM2, YKL-40, interleukins, tumor necrosis factor α, and lactoferrin for neuroinflammation due to the activation of microglia and astrocytes, and clusterin for apoptosis [113][114][115][116][117][118][119][120][121][122][123][124][125][126][127][128][129][130][131][132].…”